nodes	percent_of_prediction	percent_of_DWPC	metapath
Alosetron—CYP3A4—bone cancer	0.864	1	CbGaD
Alosetron—Ondansetron—CYP3A4—bone cancer	0.00455	1	CrCbGaD
Alosetron—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00446	0.134	CbGpPWpGaD
Alosetron—Diuresis—Cisplatin—bone cancer	0.00405	0.0413	CcSEcCtD
Alosetron—Tachyarrhythmia—Epirubicin—bone cancer	0.00353	0.036	CcSEcCtD
Alosetron—Tachyarrhythmia—Doxorubicin—bone cancer	0.00327	0.0333	CcSEcCtD
Alosetron—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00268	0.0806	CbGpPWpGaD
Alosetron—Proctitis—Epirubicin—bone cancer	0.00264	0.0269	CcSEcCtD
Alosetron—Proctitis—Doxorubicin—bone cancer	0.00244	0.0249	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—FEV—bone cancer	0.0022	0.0662	CbGpPWpGaD
Alosetron—Cognitive disorder—Methotrexate—bone cancer	0.00159	0.0162	CcSEcCtD
Alosetron—Infection—Carboplatin—bone cancer	0.00152	0.0155	CcSEcCtD
Alosetron—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00147	0.044	CbGpPWpGaD
Alosetron—Tenderness—Cisplatin—bone cancer	0.00144	0.0147	CcSEcCtD
Alosetron—Ulcer—Cisplatin—bone cancer	0.00133	0.0135	CcSEcCtD
Alosetron—Pain—Carboplatin—bone cancer	0.00131	0.0133	CcSEcCtD
Alosetron—Folliculitis—Methotrexate—bone cancer	0.0011	0.0112	CcSEcCtD
Alosetron—Nail disorder—Methotrexate—bone cancer	0.00106	0.0108	CcSEcCtD
Alosetron—Polyuria—Cisplatin—bone cancer	0.00104	0.0106	CcSEcCtD
Alosetron—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00103	0.031	CbGpPWpGaD
Alosetron—Folliculitis—Epirubicin—bone cancer	0.00103	0.0105	CcSEcCtD
Alosetron—Nail disorder—Epirubicin—bone cancer	0.000994	0.0101	CcSEcCtD
Alosetron—Burning sensation—Methotrexate—bone cancer	0.000992	0.0101	CcSEcCtD
Alosetron—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000986	0.0296	CbGpPWpGaD
Alosetron—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000985	0.0296	CbGpPWpGaD
Alosetron—Folliculitis—Doxorubicin—bone cancer	0.000949	0.00967	CcSEcCtD
Alosetron—Burning sensation—Epirubicin—bone cancer	0.000928	0.00946	CcSEcCtD
Alosetron—Nail disorder—Doxorubicin—bone cancer	0.00092	0.00937	CcSEcCtD
Alosetron—Ileus—Epirubicin—bone cancer	0.000911	0.00928	CcSEcCtD
Alosetron—Laryngitis—Epirubicin—bone cancer	0.000895	0.00911	CcSEcCtD
Alosetron—Fungal infection—Methotrexate—bone cancer	0.000892	0.00909	CcSEcCtD
Alosetron—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000882	0.0265	CbGpPWpGaD
Alosetron—Dermatitis atopic—Epirubicin—bone cancer	0.000871	0.00888	CcSEcCtD
Alosetron—Burning sensation—Doxorubicin—bone cancer	0.000859	0.00875	CcSEcCtD
Alosetron—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000846	0.0254	CbGpPWpGaD
Alosetron—Ileus—Doxorubicin—bone cancer	0.000843	0.00859	CcSEcCtD
Alosetron—Fungal infection—Epirubicin—bone cancer	0.000835	0.00851	CcSEcCtD
Alosetron—Laryngitis—Doxorubicin—bone cancer	0.000828	0.00843	CcSEcCtD
Alosetron—Cramp muscle—Cisplatin—bone cancer	0.000821	0.00836	CcSEcCtD
Alosetron—Nasopharyngitis—Cisplatin—bone cancer	0.000815	0.0083	CcSEcCtD
Alosetron—Dermatitis atopic—Doxorubicin—bone cancer	0.000806	0.00821	CcSEcCtD
Alosetron—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000792	0.0238	CbGpPWpGaD
Alosetron—Fungal infection—Doxorubicin—bone cancer	0.000773	0.00787	CcSEcCtD
Alosetron—Musculoskeletal stiffness—Methotrexate—bone cancer	0.000768	0.00783	CcSEcCtD
Alosetron—Abdominal discomfort—Cisplatin—bone cancer	0.000755	0.00769	CcSEcCtD
Alosetron—Ulcer—Methotrexate—bone cancer	0.000729	0.00742	CcSEcCtD
Alosetron—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.000708	0.0212	CbGpPWpGaD
Alosetron—Ulcer—Epirubicin—bone cancer	0.000682	0.00695	CcSEcCtD
Alosetron—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000681	0.0204	CbGpPWpGaD
Alosetron—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00068	0.0204	CbGpPWpGaD
Alosetron—Bone pain—Epirubicin—bone cancer	0.000673	0.00686	CcSEcCtD
Alosetron—Cystitis noninfective—Methotrexate—bone cancer	0.000673	0.00686	CcSEcCtD
Alosetron—Cystitis—Methotrexate—bone cancer	0.000665	0.00678	CcSEcCtD
Alosetron—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00064	0.0192	CbGpPWpGaD
Alosetron—Abnormal dreams—Epirubicin—bone cancer	0.000637	0.00649	CcSEcCtD
Alosetron—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000631	0.0189	CbGpPWpGaD
Alosetron—Ulcer—Doxorubicin—bone cancer	0.000631	0.00643	CcSEcCtD
Alosetron—Cystitis noninfective—Epirubicin—bone cancer	0.00063	0.00642	CcSEcCtD
Alosetron—Bladder pain—Methotrexate—bone cancer	0.000623	0.00635	CcSEcCtD
Alosetron—Urine output increased—Methotrexate—bone cancer	0.000623	0.00635	CcSEcCtD
Alosetron—Bone pain—Doxorubicin—bone cancer	0.000623	0.00635	CcSEcCtD
Alosetron—Cystitis—Epirubicin—bone cancer	0.000623	0.00634	CcSEcCtD
Alosetron—Colitis—Epirubicin—bone cancer	0.000619	0.00631	CcSEcCtD
Alosetron—Abnormal dreams—Doxorubicin—bone cancer	0.00059	0.00601	CcSEcCtD
Alosetron—Bladder pain—Epirubicin—bone cancer	0.000583	0.00594	CcSEcCtD
Alosetron—Cystitis noninfective—Doxorubicin—bone cancer	0.000583	0.00594	CcSEcCtD
Alosetron—Cystitis—Doxorubicin—bone cancer	0.000576	0.00587	CcSEcCtD
Alosetron—Colitis—Doxorubicin—bone cancer	0.000573	0.00584	CcSEcCtD
Alosetron—Polyuria—Methotrexate—bone cancer	0.00057	0.0058	CcSEcCtD
Alosetron—Arrhythmia—Cisplatin—bone cancer	0.000563	0.00574	CcSEcCtD
Alosetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000557	0.0167	CbGpPWpGaD
Alosetron—Alopecia—Cisplatin—bone cancer	0.000557	0.00568	CcSEcCtD
Alosetron—Flatulence—Cisplatin—bone cancer	0.000541	0.00551	CcSEcCtD
Alosetron—Bladder pain—Doxorubicin—bone cancer	0.00054	0.0055	CcSEcCtD
Alosetron—Muscle spasms—Cisplatin—bone cancer	0.000528	0.00538	CcSEcCtD
Alosetron—Eczema—Epirubicin—bone cancer	0.000521	0.00531	CcSEcCtD
Alosetron—Tremor—Cisplatin—bone cancer	0.000514	0.00524	CcSEcCtD
Alosetron—Ill-defined disorder—Cisplatin—bone cancer	0.000509	0.00519	CcSEcCtD
Alosetron—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000509	0.0153	CbGpPWpGaD
Alosetron—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000498	0.0149	CbGpPWpGaD
Alosetron—Malaise—Cisplatin—bone cancer	0.000495	0.00504	CcSEcCtD
Alosetron—Eczema—Doxorubicin—bone cancer	0.000482	0.00491	CcSEcCtD
Alosetron—Hypoglycaemia—Epirubicin—bone cancer	0.00048	0.00489	CcSEcCtD
Alosetron—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000479	0.0144	CbGpPWpGaD
Alosetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000476	0.0143	CbGpPWpGaD
Alosetron—Myalgia—Cisplatin—bone cancer	0.000467	0.00476	CcSEcCtD
Alosetron—Anxiety—Cisplatin—bone cancer	0.000466	0.00474	CcSEcCtD
Alosetron—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000463	0.0139	CbGpPWpGaD
Alosetron—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000463	0.0139	CbGpPWpGaD
Alosetron—Discomfort—Cisplatin—bone cancer	0.000462	0.0047	CcSEcCtD
Alosetron—Infection—Cisplatin—bone cancer	0.000445	0.00453	CcSEcCtD
Alosetron—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000444	0.0133	CbGpPWpGaD
Alosetron—Hypoglycaemia—Doxorubicin—bone cancer	0.000444	0.00452	CcSEcCtD
Alosetron—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000443	0.0133	CbGpPWpGaD
Alosetron—Skin disorder—Cisplatin—bone cancer	0.000435	0.00443	CcSEcCtD
Alosetron—Hyperhidrosis—Cisplatin—bone cancer	0.000433	0.00441	CcSEcCtD
Alosetron—Abdominal pain upper—Epirubicin—bone cancer	0.000428	0.00436	CcSEcCtD
Alosetron—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000425	0.0128	CbGpPWpGaD
Alosetron—Nasopharyngitis—Epirubicin—bone cancer	0.000419	0.00426	CcSEcCtD
Alosetron—Abdominal discomfort—Methotrexate—bone cancer	0.000414	0.00422	CcSEcCtD
Alosetron—Gastritis—Epirubicin—bone cancer	0.000414	0.00422	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000413	0.00421	CcSEcCtD
Alosetron—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000409	0.0123	CbGpPWpGaD
Alosetron—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000408	0.00416	CcSEcCtD
Alosetron—Abdominal distension—Epirubicin—bone cancer	0.000407	0.00415	CcSEcCtD
Alosetron—Upper respiratory tract infection—Methotrexate—bone cancer	0.000402	0.00409	CcSEcCtD
Alosetron—Abdominal pain upper—Doxorubicin—bone cancer	0.000396	0.00403	CcSEcCtD
Alosetron—Nasopharyngitis—Doxorubicin—bone cancer	0.000387	0.00395	CcSEcCtD
Alosetron—Depression—Methotrexate—bone cancer	0.000384	0.00392	CcSEcCtD
Alosetron—Gastritis—Doxorubicin—bone cancer	0.000383	0.00391	CcSEcCtD
Alosetron—Pain—Cisplatin—bone cancer	0.000383	0.0039	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000382	0.00389	CcSEcCtD
Alosetron—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000379	0.0114	CbGpPWpGaD
Alosetron—Abdominal distension—Doxorubicin—bone cancer	0.000377	0.00384	CcSEcCtD
Alosetron—Upper respiratory tract infection—Epirubicin—bone cancer	0.000376	0.00383	CcSEcCtD
Alosetron—Pollakiuria—Epirubicin—bone cancer	0.000374	0.00381	CcSEcCtD
Alosetron—Sweating—Methotrexate—bone cancer	0.00037	0.00376	CcSEcCtD
Alosetron—Feeling abnormal—Cisplatin—bone cancer	0.000369	0.00376	CcSEcCtD
Alosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000368	0.011	CbGpPWpGaD
Alosetron—Hyperglycaemia—Epirubicin—bone cancer	0.000365	0.00372	CcSEcCtD
Alosetron—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000363	0.0109	CbGpPWpGaD
Alosetron—Jaundice—Epirubicin—bone cancer	0.000352	0.00358	CcSEcCtD
Alosetron—Urinary tract infection—Epirubicin—bone cancer	0.000351	0.00357	CcSEcCtD
Alosetron—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000348	0.00354	CcSEcCtD
Alosetron—Haemoglobin—Methotrexate—bone cancer	0.000348	0.00354	CcSEcCtD
Alosetron—Haemorrhage—Methotrexate—bone cancer	0.000346	0.00353	CcSEcCtD
Alosetron—Hepatitis—Methotrexate—bone cancer	0.000346	0.00353	CcSEcCtD
Alosetron—Sweating—Epirubicin—bone cancer	0.000346	0.00352	CcSEcCtD
Alosetron—Pollakiuria—Doxorubicin—bone cancer	0.000346	0.00352	CcSEcCtD
Alosetron—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000342	0.0103	CbGpPWpGaD
Alosetron—Sinusitis—Epirubicin—bone cancer	0.000338	0.00345	CcSEcCtD
Alosetron—Hyperglycaemia—Doxorubicin—bone cancer	0.000338	0.00344	CcSEcCtD
Alosetron—Hypersensitivity—Cisplatin—bone cancer	0.00033	0.00336	CcSEcCtD
Alosetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000326	0.00977	CbGpPWpGaD
Alosetron—Haemoglobin—Epirubicin—bone cancer	0.000325	0.00332	CcSEcCtD
Alosetron—Jaundice—Doxorubicin—bone cancer	0.000325	0.00331	CcSEcCtD
Alosetron—Urinary tract infection—Doxorubicin—bone cancer	0.000324	0.00331	CcSEcCtD
Alosetron—Hepatitis—Epirubicin—bone cancer	0.000324	0.0033	CcSEcCtD
Alosetron—Haemorrhage—Epirubicin—bone cancer	0.000324	0.0033	CcSEcCtD
Alosetron—Hypoaesthesia—Epirubicin—bone cancer	0.000322	0.00328	CcSEcCtD
Alosetron—Asthenia—Cisplatin—bone cancer	0.000321	0.00327	CcSEcCtD
Alosetron—Sweating—Doxorubicin—bone cancer	0.00032	0.00326	CcSEcCtD
Alosetron—Sinusitis—Doxorubicin—bone cancer	0.000313	0.00319	CcSEcCtD
Alosetron—HTR3A—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000309	0.00928	CbGpPWpGaD
Alosetron—Alopecia—Methotrexate—bone cancer	0.000306	0.00312	CcSEcCtD
Alosetron—Haemoglobin—Doxorubicin—bone cancer	0.000301	0.00307	CcSEcCtD
Alosetron—Hepatitis—Doxorubicin—bone cancer	0.0003	0.00305	CcSEcCtD
Alosetron—Haemorrhage—Doxorubicin—bone cancer	0.0003	0.00305	CcSEcCtD
Alosetron—Hypoaesthesia—Doxorubicin—bone cancer	0.000298	0.00304	CcSEcCtD
Alosetron—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000294	0.00882	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000293	0.00879	CbGpPWpGaD
Alosetron—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00029	0.0087	CbGpPWpGaD
Alosetron—Arrhythmia—Epirubicin—bone cancer	0.000289	0.00295	CcSEcCtD
Alosetron—Alopecia—Epirubicin—bone cancer	0.000286	0.00292	CcSEcCtD
Alosetron—Vomiting—Cisplatin—bone cancer	0.000285	0.0029	CcSEcCtD
Alosetron—Rash—Cisplatin—bone cancer	0.000282	0.00288	CcSEcCtD
Alosetron—Dermatitis—Cisplatin—bone cancer	0.000282	0.00288	CcSEcCtD
Alosetron—Ill-defined disorder—Methotrexate—bone cancer	0.00028	0.00285	CcSEcCtD
Alosetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000278	0.00835	CbGpPWpGaD
Alosetron—Flatulence—Epirubicin—bone cancer	0.000278	0.00283	CcSEcCtD
Alosetron—Malaise—Methotrexate—bone cancer	0.000272	0.00277	CcSEcCtD
Alosetron—Muscle spasms—Epirubicin—bone cancer	0.000271	0.00276	CcSEcCtD
Alosetron—Arrhythmia—Doxorubicin—bone cancer	0.000268	0.00273	CcSEcCtD
Alosetron—HTR3A—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000267	0.00801	CbGpPWpGaD
Alosetron—Nausea—Cisplatin—bone cancer	0.000266	0.00271	CcSEcCtD
Alosetron—Alopecia—Doxorubicin—bone cancer	0.000265	0.0027	CcSEcCtD
Alosetron—Cough—Methotrexate—bone cancer	0.000263	0.00268	CcSEcCtD
Alosetron—Ill-defined disorder—Epirubicin—bone cancer	0.000262	0.00266	CcSEcCtD
Alosetron—Flatulence—Doxorubicin—bone cancer	0.000257	0.00262	CcSEcCtD
Alosetron—Myalgia—Methotrexate—bone cancer	0.000256	0.00261	CcSEcCtD
Alosetron—Malaise—Epirubicin—bone cancer	0.000254	0.00259	CcSEcCtD
Alosetron—Discomfort—Methotrexate—bone cancer	0.000253	0.00258	CcSEcCtD
Alosetron—Muscle spasms—Doxorubicin—bone cancer	0.000251	0.00255	CcSEcCtD
Alosetron—Confusional state—Methotrexate—bone cancer	0.000248	0.00253	CcSEcCtD
Alosetron—Cough—Epirubicin—bone cancer	0.000246	0.00251	CcSEcCtD
Alosetron—Infection—Methotrexate—bone cancer	0.000244	0.00249	CcSEcCtD
Alosetron—Hypertension—Epirubicin—bone cancer	0.000243	0.00248	CcSEcCtD
Alosetron—Ill-defined disorder—Doxorubicin—bone cancer	0.000242	0.00247	CcSEcCtD
Alosetron—Myalgia—Epirubicin—bone cancer	0.00024	0.00245	CcSEcCtD
Alosetron—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00024	0.0072	CbGpPWpGaD
Alosetron—Anxiety—Epirubicin—bone cancer	0.000239	0.00244	CcSEcCtD
Alosetron—Skin disorder—Methotrexate—bone cancer	0.000239	0.00243	CcSEcCtD
Alosetron—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000238	0.00715	CbGpPWpGaD
Alosetron—Hyperhidrosis—Methotrexate—bone cancer	0.000238	0.00242	CcSEcCtD
Alosetron—Discomfort—Epirubicin—bone cancer	0.000237	0.00242	CcSEcCtD
Alosetron—Malaise—Doxorubicin—bone cancer	0.000235	0.0024	CcSEcCtD
Alosetron—Dry mouth—Epirubicin—bone cancer	0.000235	0.00239	CcSEcCtD
Alosetron—Confusional state—Epirubicin—bone cancer	0.000232	0.00236	CcSEcCtD
Alosetron—Infection—Epirubicin—bone cancer	0.000229	0.00233	CcSEcCtD
Alosetron—Cough—Doxorubicin—bone cancer	0.000228	0.00232	CcSEcCtD
Alosetron—Hypertension—Doxorubicin—bone cancer	0.000225	0.00229	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000224	0.00228	CcSEcCtD
Alosetron—Skin disorder—Epirubicin—bone cancer	0.000223	0.00228	CcSEcCtD
Alosetron—Hyperhidrosis—Epirubicin—bone cancer	0.000222	0.00227	CcSEcCtD
Alosetron—Myalgia—Doxorubicin—bone cancer	0.000222	0.00226	CcSEcCtD
Alosetron—Anxiety—Doxorubicin—bone cancer	0.000221	0.00225	CcSEcCtD
Alosetron—Discomfort—Doxorubicin—bone cancer	0.000219	0.00224	CcSEcCtD
Alosetron—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000218	0.00656	CbGpPWpGaD
Alosetron—Dry mouth—Doxorubicin—bone cancer	0.000217	0.00221	CcSEcCtD
Alosetron—Confusional state—Doxorubicin—bone cancer	0.000215	0.00219	CcSEcCtD
Alosetron—Fatigue—Methotrexate—bone cancer	0.000212	0.00216	CcSEcCtD
Alosetron—Infection—Doxorubicin—bone cancer	0.000212	0.00215	CcSEcCtD
Alosetron—Pain—Methotrexate—bone cancer	0.00021	0.00214	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00021	0.00214	CcSEcCtD
Alosetron—Skin disorder—Doxorubicin—bone cancer	0.000207	0.00211	CcSEcCtD
Alosetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000207	0.0062	CbGpPWpGaD
Alosetron—Hyperhidrosis—Doxorubicin—bone cancer	0.000206	0.0021	CcSEcCtD
Alosetron—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000204	0.00612	CbGpPWpGaD
Alosetron—Feeling abnormal—Methotrexate—bone cancer	0.000203	0.00206	CcSEcCtD
Alosetron—Fatigue—Epirubicin—bone cancer	0.000198	0.00202	CcSEcCtD
Alosetron—Constipation—Epirubicin—bone cancer	0.000197	0.002	CcSEcCtD
Alosetron—Pain—Epirubicin—bone cancer	0.000197	0.002	CcSEcCtD
Alosetron—Urticaria—Methotrexate—bone cancer	0.000195	0.00199	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000194	0.00198	CcSEcCtD
Alosetron—Feeling abnormal—Epirubicin—bone cancer	0.00019	0.00193	CcSEcCtD
Alosetron—Fatigue—Doxorubicin—bone cancer	0.000184	0.00187	CcSEcCtD
Alosetron—Urticaria—Epirubicin—bone cancer	0.000183	0.00186	CcSEcCtD
Alosetron—Pain—Doxorubicin—bone cancer	0.000182	0.00185	CcSEcCtD
Alosetron—Constipation—Doxorubicin—bone cancer	0.000182	0.00185	CcSEcCtD
Alosetron—Hypersensitivity—Methotrexate—bone cancer	0.000181	0.00185	CcSEcCtD
Alosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000177	0.0053	CbGpPWpGaD
Alosetron—Asthenia—Methotrexate—bone cancer	0.000176	0.0018	CcSEcCtD
Alosetron—Feeling abnormal—Doxorubicin—bone cancer	0.000175	0.00179	CcSEcCtD
Alosetron—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000174	0.00523	CbGpPWpGaD
Alosetron—HTR3A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000174	0.00523	CbGpPWpGaD
Alosetron—Hypersensitivity—Epirubicin—bone cancer	0.00017	0.00173	CcSEcCtD
Alosetron—Urticaria—Doxorubicin—bone cancer	0.000169	0.00172	CcSEcCtD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000168	0.00503	CbGpPWpGaD
Alosetron—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000167	0.00501	CbGpPWpGaD
Alosetron—Asthenia—Epirubicin—bone cancer	0.000165	0.00168	CcSEcCtD
Alosetron—Hypersensitivity—Doxorubicin—bone cancer	0.000157	0.0016	CcSEcCtD
Alosetron—Vomiting—Methotrexate—bone cancer	0.000156	0.00159	CcSEcCtD
Alosetron—Rash—Methotrexate—bone cancer	0.000155	0.00158	CcSEcCtD
Alosetron—Dermatitis—Methotrexate—bone cancer	0.000155	0.00158	CcSEcCtD
Alosetron—Headache—Methotrexate—bone cancer	0.000154	0.00157	CcSEcCtD
Alosetron—Asthenia—Doxorubicin—bone cancer	0.000153	0.00156	CcSEcCtD
Alosetron—Vomiting—Epirubicin—bone cancer	0.000146	0.00149	CcSEcCtD
Alosetron—Nausea—Methotrexate—bone cancer	0.000146	0.00149	CcSEcCtD
Alosetron—Rash—Epirubicin—bone cancer	0.000145	0.00148	CcSEcCtD
Alosetron—Dermatitis—Epirubicin—bone cancer	0.000145	0.00148	CcSEcCtD
Alosetron—Headache—Epirubicin—bone cancer	0.000144	0.00147	CcSEcCtD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000143	0.0043	CbGpPWpGaD
Alosetron—Nausea—Epirubicin—bone cancer	0.000137	0.00139	CcSEcCtD
Alosetron—Vomiting—Doxorubicin—bone cancer	0.000135	0.00138	CcSEcCtD
Alosetron—Rash—Doxorubicin—bone cancer	0.000134	0.00137	CcSEcCtD
Alosetron—Dermatitis—Doxorubicin—bone cancer	0.000134	0.00137	CcSEcCtD
Alosetron—Headache—Doxorubicin—bone cancer	0.000133	0.00136	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000127	0.0038	CbGpPWpGaD
Alosetron—Nausea—Doxorubicin—bone cancer	0.000126	0.00129	CcSEcCtD
Alosetron—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000125	0.00375	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000118	0.00353	CbGpPWpGaD
Alosetron—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000111	0.00334	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000108	0.00325	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000107	0.0032	CbGpPWpGaD
Alosetron—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000106	0.00318	CbGpPWpGaD
Alosetron—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.0001	0.00301	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	9.68e-05	0.00291	CbGpPWpGaD
Alosetron—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	9.06e-05	0.00272	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.9e-05	0.00267	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.78e-05	0.00263	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	8.73e-05	0.00262	CbGpPWpGaD
Alosetron—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.75e-05	0.00233	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.61e-05	0.00228	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—CYP3A4—bone cancer	7.61e-05	0.00228	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NDUFA12—bone cancer	7.58e-05	0.00228	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.51e-05	0.00225	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	7.5e-05	0.00225	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.86e-05	0.00206	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.86e-05	0.00206	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTP1—bone cancer	6.51e-05	0.00195	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	6.42e-05	0.00193	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NT5C3A—bone cancer	6.28e-05	0.00189	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NDUFA12—bone cancer	5.34e-05	0.0016	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.02e-05	0.00151	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.95e-05	0.00149	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NDUFA12—bone cancer	4.56e-05	0.00137	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NT5C3A—bone cancer	4.42e-05	0.00133	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NT5C3A—bone cancer	3.78e-05	0.00113	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NDUFA12—bone cancer	3.52e-05	0.00106	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NT5C3A—bone cancer	2.92e-05	0.000875	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ENO2—bone cancer	2.75e-05	0.000826	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—DHFR—bone cancer	2.55e-05	0.000766	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GNA11—bone cancer	2.39e-05	0.000716	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP3A4—bone cancer	2.16e-05	0.000649	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ENO2—bone cancer	1.94e-05	0.000581	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTP1—bone cancer	1.85e-05	0.000555	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—DHFR—bone cancer	1.8e-05	0.000539	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GNA11—bone cancer	1.68e-05	0.000504	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ENO2—bone cancer	1.65e-05	0.000497	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—DHFR—bone cancer	1.54e-05	0.000461	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP3A4—bone cancer	1.52e-05	0.000457	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.51e-05	0.000455	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GNA11—bone cancer	1.43e-05	0.000431	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTP1—bone cancer	1.3e-05	0.000391	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP3A4—bone cancer	1.3e-05	0.00039	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.29e-05	0.000388	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ENO2—bone cancer	1.28e-05	0.000383	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—DHFR—bone cancer	1.18e-05	0.000356	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTP1—bone cancer	1.11e-05	0.000334	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GNA11—bone cancer	1.11e-05	0.000332	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTGS2—bone cancer	9.59e-06	0.000288	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTP1—bone cancer	8.59e-06	0.000258	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTGS2—bone cancer	6.75e-06	0.000202	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTGS2—bone cancer	5.76e-06	0.000173	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTGS2—bone cancer	4.45e-06	0.000134	CbGpPWpGaD
